Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

Every so often, activist investors swarm around underperforming companies in a certain industry and pressure them to change ...

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE ...

Biotechnology is certainly on the list, if not at the top, of high-growth industries in dire need of a rebound. Following enthusiasm for COVID-19 vaccines in late 2020 and part of 2021 ...

This is an amazing week to consider biotech stocks. Big news by the U.S. Food & Drug Administration (which we’ll get to momentarily) shows the benefits and outsized gains you can enjoy by ...

However, that all seems to be history this year as biotech stocks have begun to rebound due to a wave of FDA approvals, which started in 2023.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stock is finally on the rebound, after a long-term pullback from its Aug. 27, record high of $1,211.20.

Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how their treatments fare in Food & Drug Administration clinical ...

Biotech stocks, some of the biggest losers in the selloff, are soaring. The speculative sector is getting a boost from renewed optimism among investors. Fundamental drivers such as deal making ...

The XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13%. But there’s optimism heading into the last quarter of the year.